HHS 503A peptide policy (Oct 30, 2026): the 6 peptides, explained
On October 30, 2026, HHS published a notice in the Federal Register (document 2026-22192) announcing an interim enforcement discretion policy for compounding six peptides under section 503A of the FD&C Act. Last verified against the Federal Register text on Nov 2, 2026.
What it is, and what it is not
- HHS says it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding with the peptides in the policy's Appendix A, while the 503A bulks list is developed through rulemaking.
- It is not FDA approval. The notice states compounded drugs are not FDA-approved, and that the policy is not binding and may be revisited if a safety signal or product quality issue arises.
- FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list.
- It covers prescription compounding. It does not change the status of research-use-only (RUO) vials.
The 6 peptides
| Peptide | Dosage forms named by HHS | Research-vial $/mg | Compound guide |
|---|---|---|---|
| BPC-157 (acetate) | Subcutaneous, intramuscular, oral, topical | Compare $/mg | Guide |
| TB-500 (acetate) | Subcutaneous or intramuscular injectable | Compare $/mg | Guide |
| Epitalon (acetate) | Subcutaneous or intramuscular, intermittent courses | Compare $/mg | Guide |
| MOTS-c | See Appendix B | Compare $/mg | Guide |
| Semax | See Appendix B | Compare $/mg | Guide |
| KPV | See Appendix B | Compare $/mg | Guide |
$/mg tables list research-vial suppliers only, sorted strictly by price. For prescription routes, bloodwork labs and telehealth clinics are listed separately on Labs & Telehealth Clinics.
Sources
- Federal Register Vol. 91, No. 209 (Oct 30, 2026), doc 2026-22192
- Federal Register public inspection page for doc 2026-22192
Common questions
Which peptides are in the HHS 503A enforcement discretion policy?
BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV, per the HHS notice published in the Federal Register on October 30, 2026 (document 2026-22192).
Does this mean these peptides are FDA approved?
No. The notice states compounded drugs are not FDA-approved and that the interim policy is not binding and may be revisited.
Does the policy change research-use-only peptide vials?
No. It addresses compounding by State-licensed pharmacies, Federal facilities and licensed physicians under section 503A.
Educational summary, not legal or medical advice. Research-use-only products are not for human consumption.